Navigation Links
Jury Verdict Against Novartis Pharmaceuticals For Retaliating Against Drug Sales Rep Who Took Maternity Leave
Date:3/9/2010

WASHINGTON, March 9 /PRNewswire/ -- On March 5, 2010, a jury in the United States District Court for the District of Columbia rendered a verdict in favor of pharmaceutical sales representative Mary Kate Breeden, awarding $289,669 against Novartis Pharmaceuticals Corporation on her claim of retaliation for taking maternity leave covered by the Family and Medical Leave Act (FMLA).  Under the FMLA's liquidated damages provision, this amount is automatically doubled to $579,338.  The District Court has yet to decide the amount front pay, attorney fees, and costs to award.

Mary Kate Breeden worked as a pharmaceutical sales representative for Novartis for over seven (7) years.  After announcing that she was pregnant, Novartis cut her sales territory in half leaving her with fewer and smaller accounts.  When she objected to the change, her supervisor said it was temporary and that she would be made "whole."  Upon returning from maternity leave, Breeden was informed that the change was permanent.  Novartis reorganized the sales territories again, at which time they consolidated Breeden's territory with another and eliminated her position.  Novartis claimed that an outside consulting firm coordinated the original realignment and did not take Breeden's FMLA leave into account.  However, Breeden's maternity leave was mentioned in a PowerPoint presentation that the consulting firm prepared about the realignment.  

The jury found that Novartis retaliated against Ms. Breeden by cutting her sales territory when she announced that she was going to take leave and when Novartis refused to make her "whole" after she returned to work from FMLA leave, ultimately damaging her career and leading to her termination.  Adam Augustine Carter, a Principal at The Employment Law Group® law firm (www.employmentlawgroup.com), a premier employment law firm based in D.C., stated, "The jury of 12 believed Ms. Breeden and disbelieved the executives of Novartis in arriving at this verdict.  She was committed to her job, but her employer questioned her commitment.  No employee should have to choose between having a family or keeping their job, and this jury verdict will help teach that lesson to all employers covered by the FMLA."  

The Employment Law Group specializes in representing employees in whistleblower, wrongful termination, and discrimination cases.  To contact them regarding questions or comments, call R. Scott Oswald or Adam Augustine Carter at 202-331-3911.

SOURCE The Employment Law Group, P.C.

Back to top

RELATED LINKS
http://www.employmentlawgroup.net

'/>"/>

SOURCE The Employment Law Group, P.C.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Maryland Woman Thankful for Wyeth Verdicts
2. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
3. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
4. Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria
5. Molnlycke Drives Home the Fight Against Staph and Other MRSA Infections
6. Mayo Clinic Study Finds FDA Warning Against Anti-Nausea Drug Droperidol Unnecessary
7. Targeted Nanoparticles Offer Promise in the Battle Against Cancer
8. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
9. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
10. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
11. Semafores PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/5/2017)... , Oct. 5, 2017  In response ... of Oral and Maxillofacial Surgeons (AAOMS) released prescribing ... – to be used as a first-line therapy ... Recognizing the ... AAOMS White Paper "Opioid Prescribing: Acute and Postoperative ...
(Date:10/2/2017)... Oct. 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... Software and Consulting, LLC , and named its founder ... based in Tennessee , will operate ... expands EnvoyHealth,s service offerings for health care partners to ... "In an interoperable world, technology ...
(Date:10/2/2017)... 2, 2017 The Rebound mobile app is poised ... reverse the tide of prescription drug addiction. The app empowers ... intake and stepping down their dosage in a safe, controlled ... December 2017; the first 100,000 people to sign up will ... http://www.rebound-solution.com/ ...
Breaking Medicine Technology:
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
(Date:10/12/2017)... ... ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s premier ... of the shoulder pad. The shoulder pad provides optimal support and full contact ... using cold therapy. By utilizing ice and water that is circulated from an insulated ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
(Date:10/12/2017)... ... , ... Leading pediatric oncology experts at Children’s National Health System ... of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of the ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... nation's first interactive health literacy software tool, and the Cancer Patient Education Network ... cancer patient education, today announce a new strategic alliance. , As CPEN’s ...
Breaking Medicine News(10 mins):